New cancer clinical trial: Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Published on: March 26, 2018 at 12:00PM
Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer AJCC v6 and v7
Interventions:   Drug: Aromatase Inhibitor;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study;   Other: Questionnaire Administration;   Drug: Ribociclib
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting
https://ift.tt/2GEcwCy